Business
MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF
MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"\n \n \n \n MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Completed a Drug Master File (\"DMF\") process for CBD Active Pharmaceutical Ingredient (\"API\") for the US Federal Drug Administration (\"FDA\").\n \n \n \n \n Use of Canadian Drug Establishment Licence (\"DEL\") to register API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs.\n \n \n \n \n The cannabis-based drug opportunity is predicted to be over\n \n USD$25 billion\n \n by 2025\n \n (i)\n \n .\n \n \n \n \n This is the only US FDA for CBD by a Canadian company and the second natural CBD DMF at commercial scale in all of\n \n North America\n \n \n (ii)\n \n .\n \n \n \n \n TORONTO\n \n ,\n \n Feb. 23, 2022\n \n /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (\"MediPharm\" or the \"Company\") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over\n \n USD$25 billion\n \n by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects will all require pharmaceutical approved API if commercialized. MediPharm has already shipped good manufacturing practice (\"GMP\") CBD for development purposes to multiple established pharmaceutical companies.\n \n \n \n \n \n \n \n \n \n \n Management Commentary\n \n \n \n \n \n Bryan Howcroft\n \n , CEO, ...